Specialty Pharma Journal Specialty, Precision & Technology
A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report. The cancer, called p53-like bladder cancer, is named after an active gene signature it is associated with. It is often particularly aggressive, though individual prognoses can vary quite a bit. …
Tag Archives: bladder cancer
July, 2018
November, 2017
-
10 November
Bristol-Myers Squibb Announces Encouraging Results for Opdivo Plus Investigational IDO1 Inhibitor in Advanced Cancers
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results for Opdivo (nivolumab) plus BMS-986205, a selective, once-daily oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor from the ongoing Phase 1/2a dose escalation and expansion study, CA017-003. In the dose escalation phase, the maximum tolerated dose (primary endpoint) of BMS-986205 in combination with Opdivo was 200 mg. …
July, 2017
-
7 July
Simple Test Predicts Return of Bladder Cancer
Scientists have devised a simple test for an earlier and more accurate warning of returning bladder cancer than existing methods, according to research* published in the British Journal of Cancer today (Friday). Researchers from the University Hospital of Lyon tested the urine of 348 bladder cancer patients for a faulty protein called …
May, 2017
-
31 May
Lilly’s Cyramza Meets Primary Endpoint in Late-Stage Urothelial Cancer Trial
INDIANAPOLIS, May 31, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RANGE study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement. The Phase 3 global, randomized, double-blinded, placebo-controlled trial is evaluating ramucirumab in combination with …
-
19 May
FDA Approves Merck’s Keytruda for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved two new indications for KEYTRUDA®(pembrolizumab), the company’s anti-PD-1 therapy, for certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. In …
-
10 May
Genentech’s Tecentriq Misses Primary Endpoint in Late-Stage Bladder Cancer Study
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX:RO, ROG; OTCQX:RHHBY), today announced that the Phase III IMvigor211 study that evaluated TECENTRIQ® (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed during or after treatment with a platinum-based chemotherapy (previously treated) did …
-
9 May
FDA Approves Pfizer’s Bavencio for Treatment of Patients with Advanced Bladder Cancer
ROCKLAND, Mass. and NEW YORK, May 9, 2017 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection for the treatment of patients …
-
3 May
Altor BioScience’s Investigational Bladder Cancer Drug Granted Fast Track Status from the FDA
MIRAMAR, Fla.–(BUSINESS WIRE)–Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational interleukin-15 (IL-15) agonist complex, ALT-803, in combination with bacillus Calmette-Guérin (BCG), for …
-
1 May
FDA Grants Accelerated Approval to AstraZeneca’s Imfinzi for Advanced Bladder Cancer
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to IMFINZI™ (durvalumab). IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following …
April, 2017
-
18 April
FDA Grants Accelerated Approval to Genentech’s Tecentriq for Treatment of Advanced Bladder Cancer
South San Francisco, CA — April 17, 2017 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who …